- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- 【Updated on June 30, 2025】Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
-
- UEDA Yasushi
- Tokyo Jikei University School of Medicine, Second Internal Medicine
-
- TOJO Shizuo
- Institute of Clinical Medicine, The University of Tsukuba
-
- HATANO Michinobu
- The 2 nd Department of Internal Medicine, Nihon University School of Medicine
-
- FURUKAWA Toshiyuki
- Institute of Medical Electronics, Faculty of Medicine, University of Tokyo
-
- YOSHINAGA Kaoru
- The 2 nd Department o f Internal Medicine, T ohoku University School o f Medicine
-
- KINOSHITA Yasutami
- Second Department of Internal Medicine, Niigata University School of Medicine
-
- TAKEUCHI Jugoro
- Second Department of Internal Medicine, Tokyo Medical and Dental University
-
- KATO Eiichi
- Department of Internal Medicine, School of Medicine, Keio University
-
- OHNO Joji
- Department of Internal Medicine, Devision of Nephrology, Juntendo University, School of Medicine
-
- KOBAYASHI Kaizo
- Department of Internal Medicine, Nagoya University Branch Hospital
-
- ABE Hiroshi
- The 1st Department of Medicine, Osaka University Medical School
-
- OMAE Seruo
- The 2 nd Department of Internal Medicine, Kyushu University
Bibliographic Information
- Other Title
-
- ネフローゼ症候群におけるDipyridamole (Persantin®)の臨床効果
- ネフローゼ ショウコウグン ニ オケル Dipyridamole Persan
- Multiclinic Double Blind Test
- ―多施設二重盲検試験―
Search this article
Description
Dipyridamole (Persantin) 300 mg/day, or its placebo were administered for 4 weeks to the nephrotic syndrome who had been treated by corticosteroids and their effects were compared by double blind method. 1) General improvement rate of Persantin (88.2%) was significantly (p<0.05) higher than that of placebo (46.7%) in steroid unresponsive nephrotic syndrome group. 2) As to urinary protein decreasing effect indicated by average decreasing rates of urinary protein in a week, the effect was better in Persantin group than in placebo group in the 1st and 2nd week. The same results were confirmed more evidently in the steroid unresponsive nephrotic syndrome group and also in those patient except minimal changes in histological classification. 3) As to the endogenous creatinine clearance, Persantin group showed a significantly large increase, compared with placebo group. 4) As to serum cholesterol level and triglycerid level, Persantin group showed a bigger tende-ncy to decrease, compared with placebo group. 5) As for side effects, headache, palpitation, nausea, retching, and others were observed in Persantin group. However, these were not serious and disappeared after discontinuation of administra-tion of the drug.
Journal
-
- The Japanese Journal of Nephrology
-
The Japanese Journal of Nephrology 21 (11), 1171-1183, 1979
Japanese Society of Nephrology
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390282679838167936
-
- NII Article ID
- 130004168432
-
- NII Book ID
- AN10131749
-
- ISSN
- 18840728
- 03852385
-
- NDL BIB ID
- 2204018
-
- PubMed
- 396401
-
- Article Type
- journal article
-
- Data Source
-
- JaLC
- NDL Search
- PubMed
- CiNii Articles
-
- Abstract License Flag
- Disallowed